SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharmaceuticals informs about newspaper clippings

27 Jul 2024 Evaluate

With reference to letter No. JPL/CS/2110/2024 dated 26th July, 2024, Jenburkt Pharmaceuticals has informed that it enclosed clippings of two Newspapers, The Free Press Journal, Mumbai (English) and Navshakti, Mumbai (Marathi) dated 27th July, 2024 containing the standalone Unaudited Financial Results of the Company for the quarter ended on 30th June, 2024. 

The above information is a part of company’s filings submitted to BSE.

Jenburkt Pharma Share Price

1050.40 24.80 (2.42%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×